Roche

Roche Invests $50 Billion in Pharmaceuticals & Diagnostics

Roche recently announced that it will invest $50 billion (€43.8 billion) into the United States in the next five years.

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Innovent Licenses Lung Cancer Therapy Candidate to Roche

Chinese biopharmaceutical company Innovent Biologics announced a collaboration and exclusive license agreement with Roche to advance the development of IBI3009, a novel DLL3-targeted antibody-drug conjugate (ADC) candidate.

Roche to Buy Poseida Therapeutics for $1.5 Billion

Roche has entered into a definitive merger agreement to acquire Poseida Therapeutics, a US clinical-stage biopharmaceutical company developing donor-derived CAR-T cell therapies, in a deal valued at approximately $1.5 billion.

Lonza Completes Acquisition of Vacaville Biologics Site from Roche

Lonza has completed its acquisition of the Genentech large-scale biologics manufacturing site in Vacaville, California, USA, from Roche for $1.2 billion. The deal was announced in March of this year.

Roche to Acquire Obesity Drug Maker Carmot

In a move to participate in the race for anti-obesity drugs, Swiss pharma giant Roche has agreed to acquire Carmot Therapeutics, a privately owned US company based in Berkeley, California.

Roche and Sysmex Expand Long-Term Alliance

Pharmaceutical group Roche and Japanese diagnostics company Sysmex are expanding and extending their existing long-standing partnership. Under the renewed terms of the non-inclusive agreement, Roche will continue to offer Sysmex's hematology products, which complement the company's laboratory solutions portfolio, they said in a statement yesterday.

Roche Teams up with Alnylam for Antihypertensive Drug

Swiss pharmaceutical company Roche will collaborate with Cambridge, Massachusetts-based US biotech Alnylam Pharmaceuticals to further develop its drug zilebesiran for the treatment of hypertension. The therapeutic, which is in Phase 2 clinical trials, uses the cellular mechanism RNA interference (RNAi) for targeted gene silencing.

Navigating Uncertainty in the Biopharma Market

Biopharma companies are facing funding challenges in 2023 as interest rates rise and investors are becoming more risk adverse. There is hope on the horizon, say some analysts, while others project a prolonged slump due to inflation and global instability. Established pharmaceutical companies are often seen as safer investments, with larger developers expected to perform well in 2023, especially if litigation threats against drugs like Zantac disappear. However, concerns about revenue gaps continue for big companies like GSK and Sanofi, and their strategy and leadership will be closely monitored in the coming months.

Another Turbulent AGM for Bayer?

Bayer has seen its share of turbulent shareholder meetings, and the event on Apr. 28 is likely to continue in that vein, though it would be tough to top 2019. In that year, when anger over lawsuits involving Monsanto’s Roundup herbicide boiled over, 55% voted not to discharge CEO Werner Baumann and the managing board of their responsibilities.

New Biotech VC Vehicle Pledges Series A Funding Aid

A new venture capital vehicle launched by a group of biotech entrepreneurs is designed to act as a seed investor as well as a drug discovery co-pilot for biotech startups that need help with Series-A financing.

Genentech Builds Biologics Facility in California

Genentech, the US biotech arm of Swiss pharma giant Roche, is building a new small-batch biologics manufacturing facility at its Oceanside campus in California, USA. Groundbreaking took place on Feb. 10.

Bill Anderson to Be Bayer CEO from June 1

Bowing to growing pressure from activist investors with different missions, the supervisory board of tradition-steeped German pharmaceuticals and agrochemicals player Bayer has announced the appointment of a new CEO to succeed embattled incumbent Werner Baumann — a year before the end of the current chief executive’s regular term.

Pharma CEOs Take Action on Climate Change

The CEOs of seven multinational pharmaceutical companies have announced that they are taking joint action to achieve near-term emissions reduction targets and accelerate the delivery of net zero health systems.

GSK Names Julie Brown as First Female CFO

From next year, GSK’s top management will be led by a double female team, a pioneering move for the global pharmaceutical industry. The UK drugs giant this week announced the appointment of Julie Brown, the first woman to be its chief financial officer.

Roche Launches Genomic Profiling Kit for Cancer Analysis

Swiss drugmaker Roche has launched a genomic profiling kit that it has developed in conjunction with Foundation Medicine. The Basel-based company is supplying the kit across Europe, North America, South America and Asia.

Roche Acquires Irish Biotech Inflazome

Swiss drugmaker Roche has acquired Irish biotech Inflazome for €380 million, said to be one of the largest deals in Irish biotech history. Headquartered in Dublin, Inflazome regards itself as a leader in the development of inflammasome inhibitors.

Celleron Takes Roche Cancer Drug

UK biopharma Celleron Therapeutics has signed a licensing deal with Roche, gaining exclusive worldwide rights to the Swiss pharma’s monoclonal antibody emactuzumab, which is designed to target and deplete macrophages in solid tumors.

Roche in Cancer and Immunology Collaborations

Roche has announced two separate collaborations, one for an investigational cancer treatment and the other for the discovery of small molecule drugs for treating immune-mediated and neurological diseases.

Pierre-Alain Ruffieux new CEO of Lonza

Roche Links with Vividion on E3 Ligases

Roche and Arrakis Link on RNA-targeted Drugs

Roche Boosts Fibrotic Diseases with Promedior

Made in Switzerland – Exported Worldwide

Sanofi Buys Nonprescription Rights to Tamiflu

Roche Pays $4.3 Billion for Spark Therapeutics

Gilead Nabs Roche Pharma Chief

FDA Greenlights Bayer-Loxo’s Vitrakvi

A Wide Spectrum of Contract Services

Affimed and Genentech in Immunotherapy Pact

Roche Links with PureTech on Exosomes

Roche Buys Rest of Foundation Medicine

Digitization’s Impact on the Pharmaceutical Industry

Along the Acquisition Trail

Roche to Buy New York’s Flatiron Health